GLI1 and neoplasm: SOCS1, an IFN-γ/STAT1 inhibitor, is activated by HH signaling pathway itself to create a negative feedback loop and a downstream target of GLI1 and GLI2, which upregulates its transcriptional activity and subsequently relieve the IFN-γ/STAT1 form obstructing tumor growth [142].